Compounds > nelfinavir
Page last updated: 2024-08-24

nelfinavir and pyrazines

nelfinavir has been researched along with pyrazines in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M1
Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H1
Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W1
Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT1
Brüning, A; Friese, K; Rahmeh, M1

Other Studies

5 other study(ies) available for nelfinavir and pyrazines

ArticleYear
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Current cancer drug targets, 2011, Volume: 11, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms

2011
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Haematologica, 2012, Volume: 97, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays

2012
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
    Cell death & disease, 2012, Jul-19, Volume: 3

    Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous

2012
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays

2013
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
    Molecular oncology, 2013, Volume: 7, Issue:6

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation

2013